

## INDEX

---

Note: Page numbers in *italics* indicate figures.  
Page numbers followed by a “t” indicate tables.

- Abaloparatide (PTHrP[1-34]), 181t, 234, 237-239. See also  
*Parathyroid hormone (PTH)*.  
action mechanism, 237  
approved indications, 234, 237  
black box warning, 237  
contraindications and cautions, 238-239, 270  
dosage, 181t, 239  
efficacy, 238, 240-241  
side effects, 238-239
- Acidic environment, created by osteoclasts, 26, 259
- ACTIVE trials, 238, 240-241
- Activities of daily living, 140
- Actonel. See *Risedronate*.
- Adolescence  
bone mass in, 24, 46  
bone remodeling in, 24
- Adrenal function tests, 88
- Advanced glycation end products (AGEs), 270
- Adynamic bone disease, 271
- Age/aging. See also *Elderly persons*.  
bone loss, 43, 45, 72, 267  
bone mass, 44  
bone remodeling, 23-24, 24, 25  
osteopenia and, 13  
for osteoporosis screening, 107-108, 107t  
peak bone mass, 23, 24, 44
- Alcohol intake  
falls, risk of, 51  
osteoporosis/fracture risk and, 62t, 63, 86, 268  
recommendations, 280
- Alendronate, 180t, 185-193. See also *Bisphosphonates*.  
approved indications, 180t, 185, 191  
for men, 185, 268  
prevention and treatment of GIOP, 276  
chemical structure, 184  
discontinuation of treatment, 190-191, 190

- Alendronate (*continued*)  
 dosage, 180t, 187-190, 191-193  
 daily dosing, 187  
 once-weekly dosing, 187-190  
 efficacy, 180t, 185-187  
 bone mineral density, 187-190, 188-189  
 fracture risk reduction, 180t, 187, 190, 192  
 glucocorticoid-induced osteoporosis, 191, 192, 276  
 formulation with vitamin D, 192-193  
 long-term use, “drug holiday” for, 206, 245  
 side effects, 180t
- Alendronate/cholecalciferol, 180t
- Alkaline phosphatase, 23  
 as bone formation biomarker, 128t, 129  
 bone-specific (BSAP), 128t
- Aluminum, 62t, 271
- Amenorrhea, exercise-induced, 60t, 66
- American Association of Clinical Endocrinology (AACE),  
 osteoporosis screening recommendation, 107-108
- Androgens  
 age-related decrease in, 268  
 androgen deprivation therapy, 285-286  
 hypogonadal states, 60t
- Anorexia nervosa, 60t, 65-66
- Anterior uveitis, 210
- Anticoagulants, 62t
- Anticonvulsants, 62t, 67
- Antiepileptic drugs, 269, 286
- Antiresorptive agents, 179, 180t-181t, 183-233. See also  
*specific drug classes and agents*.  
 approved indications, 179, 180t-181t  
 combinations not recommended, 182-183  
 drug classes, 179, 180t-181t  
 bisphosphonates, 180t, 183-210  
 calcitonin, 181t, 227-229  
 cathepsin K inhibitor (odanacatib), 260, 261  
 other drugs, 181t  
 postmenopausal hormone replacement therapy, 179,  
 231-233  
 RANKL inhibitor (denosumab), 181t, 214-227  
 selective estrogen receptor modulators, 181t, 210-214  
 tyrosine src kinase inhibitor (saracatinib), 260, 261
- Antiresorptive agents (*continued*)  
 efficacy, 181t  
 novel therapies and targets, 260-261, 260  
 PTH in combination with or following, 239-243, 242, 243
- Antitransglutaminase antibodies, 86
- Appendicular skeleton, 19, 20  
 cortical bone in, 22
- Arimidex, 281
- Aromatase inhibitors, 62t, 281-285
- Arthralgias, 210
- Arthritis, 269
- Asian women, osteoporosis risk and, 11, 59
- Asthma, 268-269
- Astronauts, 37
- Athletes  
 amenorrhea in, 60t, 66  
 female athletic triad, 66
- Atrial fibrillation, 207
- Autoimmune diseases, 61t
- Axial skeleton, 19, 20  
 trabecular bone in, 22
- Back pain, 59, 73, 137. See also *Pain*.  
 causes of, 73, 139  
 chronic, 137
- Balance. See also *Falls*.  
 falls prevention and, 140-141  
 leg length disparity and, 73, 76-77  
 training and physical therapy for, 139-140
- Balicatib, 261
- Barbiturates, 62t
- Basic multicellular unit (BMU), 31
- BGP (bone GLA-protein). See *Osteocalcin*.
- Biochemical markers of bone remodeling, 127-135, 128t  
 bone formation, 128t, 129  
 bone resorption, 128t, 129-131, 130
- Bisphosphonates, 180t, 183-210. See also *Antiresorptive agents; specific agents*.  
 absorption of, 185  
 action mechanisms, 184-185, 186  
 approved indications, 180t, 280  
 cautions and contraindications, 203, 207, 273

Bisphosphonates (*continued*)  
chemical structures, 184  
in children, 210  
dosage, 180t  
efficacy, 180t, 185-210, 285  
as first-line treatment, 182  
generations of  
  first generation, 183  
  second generation, 183  
  third generation, 184  
long-term use, 133, 244-245  
  “drug holiday” for, 133, 206, 245  
pharmacology, 183-185, 184  
side effects and safety issues, 15, 180t, 204-210, 244-245  
  anterior uveitis, 210  
  arthralgias, 210  
  atrial fibrillation, 207  
  atypical femoral fractures, 206, 208-209, 245  
  fracture healing, 209  
  gastrointestinal effects, 204-205  
  hypocalcaemia, 210  
  osteonecrosis of the jaw (ONJ), 205-206, 205, 245  
  post infusion acute phase reactions, 207  
  renal impairment, 207, 273  
  suppression of bone remodeling, 133  
  specific agents, 180t  
Blood pressure, 72-73  
BMD. See *Bone mineral density*.  
BMI. See *Body mass index*.  
Body mass index (BMI), 72-73  
  osteoporosis risk and, 14, 63  
Body weight, 62t, 72-73  
Bone, 19-42. See also *Cortical bone; Trabecular bone; and other bone entries*.  
  anatomical structure, 19, 20  
  architectural structure, 19-22, 21  
  cells. See *Osteoblasts; Osteoclasts; Osteocytes*.  
  chemical structure, 22-23  
  cortical bone, 19-22, 21  
  embryological structure, 19  
  functions of, 19  
  intramembranous vs endochondral bone, 19

Bone (*continued*)  
  mineral composition of, 149  
  structure of, 19-23  
  trabecular bone, 22, 43-44  
Bone densitometry. See *DXA*.  
Bone density, 81  
Bone formation, 23. See also *Bone remodeling*.  
  biochemical markers of, 128t, 129  
  in bone remodeling cycle, 33, 34-35  
  inadequate, 48-49. See also *Osteopenia*.  
  stimulants of, 179, 181t, 245. See also *Androgens; Parathyroid hormone*.  
Bone fragility, 11  
Bone GLA-protein. See *Osteocalcin*.  
Bone homeostasis, 36, 271  
Bone loss. See also *Bone remodeling; Risk factors for osteoporosis*.  
  accelerated, 47-48  
  aromatase inhibitors and, 281-285  
  in astronauts, 37  
  asymptomatic, 14  
  cancer chemotherapy and, 281, 284  
  in children, 268-270  
  chronic kidney disease and, 271-273  
  drugs and, 273-287  
  glucocorticoids and, 49, 274, 275, 276  
  hyperparathyroidism and, 271-273, 272  
  hyperprolactinemia and, 66  
  immunosuppressive therapy and, 280-281  
  medications and, 268-269, 273-287  
  postmenopausal, 43  
  risk factors for, 60t-62t  
  secondary, 267  
  thyroid hormones and, 36  
Bone marrow, 35  
Bone mass  
  age and, 44  
  antiresorptive agents and, 181t, 227-229  
  in children and adolescents, 268-270  
  exercise and, 46-47, 137-138  
  female athletic triad and, 66  
  fracture risk and, 89-90

### Bone mass (*continued*)

- gynecologic factors in, 63-65t
- lifestyle and, 63
- medications associated with, 13-14, 59, 67
  - glucocorticoids, 32, 48, 49, 268-269, 274
- peak
  - achieving before menopause, 137
  - age at, 23, 24, 63
  - failure to achieve, 44-47
  - genetics and, 46, 63, 268
  - reference values, 83, 89
  - reporting of, 88-89
  - T-scores vs Z-scores, 82t, 83

### Bone mass measurement. See also *DXA*.

- osteoporosis screening, age for, 107-108, 107t
- technology/techniques, 14

### Bone matrix

- constituents/synthesis, 26, 29
- mineral to matrix ratio, 50

### Bone metabolism, endocrine factors in, 35-36

### Bone mineral density (BMD), 68-69, 88-90. See also *Bone mass*; *DXA*; *Fracture risk*.

- bone strength and, 89
- exercise and, 127-128
- loss with age, 267
- measured by DXA, 14, 68-69, 70t
- medications and, 274
- in men, 86, 267-268
- as predictive of fracture risk, 14, 59, 89-90
- sites recommended for, 83
- T-scores, 81-83, 82t

### Bone morphogenetic proteins, 28

### Bone quality, 49-50, 81

### Bone remodeling, 23-35. See also *Bone formation*; *Bone resorption*.

- acidic environment for, 26
- age and gender in, 23-24, 24, 25
- basic multicellular unit (BMU) in, 31, 34
- biochemical markers of, 127-135, 128t
  - bone formation, 128t, 129
  - bone resorption, 128t, 129-131

### Bone remodeling (*continued*)

- bone remodeling cycle, 31-35, 33
  - activation, 32-34, 33
    - osteoblast activation and osteoid formation, 33, 34-35
    - osteoclast activation and resorption, 33, 34, 259-260, 260
    - quiescence, 35
- bone resorption in, 44, 260
- cells regulating, 24-31
- endocrine factors in, 35-36
- exercise and, 36-37
- mechanical stress and, 36-37
- osteoblasts in, 26-31, 33, 34-35, 127, 259, 262, 263
- osteoclasts in, 24-26, 27, 33, 34, 127, 259-261, 260
- suppression of, 127, 133

### Bone resorption, 44, 260. See also *Antiresorptive agents*;

- Bone loss*.
  - accelerated, 47-48
  - antiresorptive agents, 179, 180t-181t, 260-261
  - cathepsin K in, 259, 260, 261
  - markers of, 128t, 129-131, 130

### Bone-specific alkaline phosphatase (BSAP), 128t

### BONE study (Oral Ibandronate), 196

### Bone strength

- BMD and, 89
- changes with age, 25

### Bone turnover markers (BTM), 127-135, 128t

- in clinical practice, 131-133
- formation markers, 128t
- lack of standardized testing, 131-132
- in monitoring osteoporosis therapy, 132-133
- as predictors of fracture risk, 127, 132
- resorption markers, 128t, 129-131, 130

### Boniva. See *Ibandronate*.

### Breast cancer, 281-285

- aromatase inhibitors and, 281-285
- aromatase inhibitors in therapy for, 281
- raloxifene, reduction of breast cancer risk, 210, 212
- risk, 231-233, 232
- tibolone and, 214

### C-carboxytelepeptide (CTX), 128t, 130, 131

### C-telopeptide, 130, 217, 219

- Caffeine intake, 63
- Calcaneus, QUS of, 106, 110, 112
- Calcilytic drugs, 265
- Calcitonin, 181t, 227-229
  - action mechanisms, 36, 227
  - dosage and administration, 229
  - efficacy, 181t, 227-228
    - intranasal, 228
    - parenteral, 227-228
  - indications for, 181t
  - salmon calcitonin (SCT), 181t, 227
  - side effects, 181t, 228
- Calcium, 149-162. See also *Vitamin D*.
  - absorption of, 156
    - aging and, 163
  - calcium calculator, 149, 152-155
  - deficiency, 46-47
  - Dietary Reference Intakes for, 149, 150t-151t
    - for postmenopausal women, 149
  - dietary sources, 149, 158
    - milk and dairy products, 160
  - food label, 156, 157
  - fracture reduction and, 158-160, 159
  - intake, 156-158
    - cardiovascular concerns, 160-162
    - daily need for, 156
    - dietary reference guidelines, 150t-151t
    - low, as risk factor for osteoporosis, 60t, 63
    - necessary for efficacy of anti-osteoporosis medications, 15
    - recommended daily, 150t-151t, 158, 160
      - in special populations, 269, 270, 276-280, 281-285, 286
    - supplementation for, 63, 158
  - malabsorption of, 67
  - measurements of, in diagnosis, 86, 87t
  - parathyroid hormone (PTH) and, 262, 265
  - percentage in skeleton and hydroxyapatite, 149
  - supplementary, 63, 158
    - bioavailability of, 158
    - calcium-fortified beverages, 158
    - recommendations on, 158, 160
    - side effects and concerns, 160-162
  - vitamin D necessity for absorption of, 156
- Calcium-sensing receptor (CaSR), 262, 263, 264-265
- Canagliflozin, 287
- Cancellous bone. See *Trabecular bone*.
- Cancer
  - breast, 231-233, 232, 281-285
  - chemotherapy, 269, 281, 284
  - in children/adolescents, 269
  - disability from, 13
  - prostate, 228, 268, 285
- CANVAS trial, 287
- Cardiovascular disease (CVD)
  - calcium supplementation and, 160-162
  - denosumab and, 220
  - PTH and, 246, 272
  - raloxifene and, 210, 212
  - strontium and, 231
  - thiazolidinediones and, 280
- Caspase system, bisphosphonates and, 185, 186
- CaSR. See *Calcium-sensing receptor*.
- Cathepsin K, 26, 259, 260, 261
  - inhibitor of (odanacatib), 260, 261
- Caucasian women, osteoporosis risk and, 11, 59
- Celiac disease, 67, 86, 268
- Centers for Medicare & Medicaid Services (CMS), 108-109, 109t
- Central nervous system disorders
  - falls and, 51
  - osteoporosis/fracture risk and, 61t
- Chemotherapy, 62t, 281, 284
- Chief cells, 35
- Childbirths, 64
- Children, 268-270
  - bone modeling in, 23
- Chronic kidney disease (CKD), 271-273, 272
- Chronic kidney disease-mineral and bone disorder (CKD-MBD), 271
- Cinacalcet, 273
- Clinical evaluation. See *Diagnosis of osteoporosis*.
- Clodronate, 183, 184, 203
- Collagen, 22, 49-50, 127, 270
  - cathepsin K and, 261
  - cross-links, 50, 128t, 129-131

Collagen (*continued*)  
 fractures and, 49-50  
 procollagen I terminal peptides, 128t, 129, 130  
 CORE (Continuing Outcomes Relevant to Evista), 211-212  
 Cortical bone, 19-22, 21  
 loss of, 44, 45  
 percentage in different bones, 20, 22  
 Corticosteroids. See *Glucocorticoids*.  
 CTX (C-terminal cross-linking telopeptide), 128t, 130, 131, 219  
 Cushing's disease, 48, 61t, 88, 268  
 Cyclosporine, 62t

Daily living, activities of, 140  
 DALYs (disability and life-years lost), 11-13, 12  
 Dapagliflozin, 287  
 DATA study, 220-225, 222-223, 224, 226  
 Definition of osteoporosis, 81-83, 82t  
 Denosumab (RANKL inhibitor), 181t, 214-227  
 action mechanism, 214-215, 216, 260, 260  
 approved indications, 181t, 214, 280  
 in CKD, 273  
 DATA study, 220-225, 222-223, 224, 226  
 discontinuing treatment, 220-225, 222-223, 224, 226  
 dosage and administration, 181t, 225-227  
 efficacy, 181t, 215-220  
 bone mineral density, 215-220, 285  
 fracture risk reduction, 215-220, 217, 218t  
 FREEDOM trial, 215-220, 217, 218t  
 indications for, 260  
 androgen deprivation therapy, 285  
 in men, 268  
 as second-line treatment, 182  
 long-term therapy, 245  
 drug "holiday" NOT recommended, 245  
 side effects, 181t, 220  
 Densitometry. See *DXA*.  
 Dental hygiene, 205-206  
 Deoxyypyridinoline (DPD), 128t, 130, 131  
 DEXA. See *DXA*.  
 Diabetes, 270  
 as risk factor, 61t

Diagnosis of osteoporosis, 59-135  
 after first clinical fracture, 14  
 assessment tools, 109-115  
 biochemical markers of bone remodeling, 127-135  
 in clinical practice, 131-133  
 bone densitometry, 14, 49, 88-106. See also *DXA*.  
 bone mass, 89-90  
 reporting and reference values, 88-89  
 bone mineral density (BMD)  
 DXA measurement of, 14, 68-69, 88-106  
 T-scores, 81-83, 82t, 88-89  
 definition of osteoporosis, 81-83, 82t  
 DXA, 88-106  
 interpretation of, 90-106  
 screening and retesting, 106-110  
 sites recommended for, 83, 90, 92-97  
 fracture risk assessment tools, 109-115  
 fracture types, 84-86, 85  
 fragility fractures, 84-86, 85  
 FRAX as risk assessment tool, 14, 68-71, 69, 70t-71t, 102  
 history, 59, 60t-62t  
 musculoskeletal examination, 73, 76-77  
 patient evaluation, 59  
 physical examination, 72-73, 74t  
 leg-length discrepancies, 73, 76-77  
 risk factors, 63-68  
 eating disorders, 65-66  
 endocrinopathies, 61t, 66  
 fall risk factors, 67-68  
 gastrointestinal diseases, 61t, 67  
 genetics, 60t, 63  
 gynecologic risk factors, 63-65  
 lifestyle risk factors, 63  
 medications, 62t, 67  
 modifiable risk factors, 63  
 screening and retesting, 106-110  
 secondary causes of osteoporosis, 86-88  
 laboratory tests for, 87t  
 T-scores and Z-scores, 81-83, 82t, 88-89  
 vertebral fracture assessment (VFA), 95, 114-115, 116-117, 118t, 120-121  
 Dickkopf-1. See *DKK1*.

- Diet, 63, 149
  - calcium in, 149-162
  - sources of, 149
  - vitamin D in, 162-169
  - sources of, 163
- Disability, 11-13, 12
  - disability and life-years (DALYs) lost, 11-13, 12
- Dizziness, 51, 68
- DKK1 (dickkopf-1), 31, 262, 263, 264
  - antibody against (BHQ 880), 263, 264
- Dorsal kyphosis, 73
- Drug therapy. See *Pharmacologic treatment*.
- Drugs that increase fracture risk, 273-287. See also *Medications*.
- Dual-energy x-ray absorptiometry. See *DXA*.
- DXA (dual-energy x-ray absorptiometry), 14, 49, 81, 88-106
  - advantages of, 88
  - best practices for, 104, 105t
  - fracture risk assessment with, 89-90
  - indications for, 88, 106-110
    - from CMS, 108-109, 109t
  - interpretation of, 90-106, 105t
    - assessment of change, 103-104
    - certification for, 91
    - comparisons with other scanners, 103-104
    - forearm analysis, 103
    - general analysis, 91
    - hip analysis, 96-102
    - lumbar spine analysis, 91-96
    - patient information sheet, 98-101
    - quality assurance for, 104
    - reference values, 89
  - in pediatrics, 89
  - peripheral DXA, 106-107
  - quality of, 104, 105t
  - reference values, 89
  - reporting of, 88-89, 106
  - screening recommendations, 106-110, 107t, 109t
  - screening tests compared, 106-107
  - sites recommended for, 83, 90, 92-97
    - forearm, 90, 96-97
    - hip, 90, 94-95
    - spine, 90, 92-93
- DXA (dual-energy x-ray absorptiometry) (*continued*)
  - T-scores, 70t, 81-83, 82t, 88-89
  - Z-scores, 81-83, 88-89
- Eating disorders, osteoporosis/fracture risk and, 60t, 65-66
- Elderly persons. See also *Age/aging*.
  - falls
    - prevention programs, 140-141
    - risk of, 50-51, 52-53, 67-68
  - fractures in, morbidity and, 11
  - walking speed and falls in, 52-53
- Empagliflozin, 287
- Endochondral bone, 19
- Endocrine factors in bone metabolism, 35-36, 61t, 66
- Endosteum, 21, 21
- Epilepsy, 269
- Estrogen. See also *Hormone therapy*.
  - bone metabolism and, 36
  - deficiency, 43, 47, 48, 64
  - osteoblasts/osteoclasts/osteocytes, effects on, 36, 47
  - selective estrogen receptor modulators (SERMs), 181t, 210-214
- Ethnicity
  - DEXA reference values, 83, 89
  - osteoporosis risk and, 11, 59
  - Z-scores, 89
- Etidronate, 183, 203-204
  - chemical structure, 184
  - dosage, 204
  - not FDA approved in the United States, 203-204
  - off label use, 204
- EUROFORS, 239-243
- Evista. See *Raloxifene*.
- Exercise, 137-140
  - in adolescents/teens, 46-47
    - balance training, 139-140
  - bone mass and, 46-47, 137-138
  - fracture risk and, 49, 138
  - high-impact, 137-138
  - lack of, 46-47, 49, 60t
  - osteoporosis exercise program, 138-140
  - physical therapist and, 139, 140

Exercise (*continued*)

- for postmenopausal women, 138-139
- for premenopausal women, 137-138
- site-specific, 139-140
- strength training, 138-139
- walking, 138, 140
- weight-bearing, 138, 139

Falls, 60t, 67-68, 140-141

- balance and, 140-141
- eliminating, 51
- factors in, 50-51, 67-68
  - central nervous system disorders, 51
  - dizziness, 51, 68
  - medications, 51
  - muscle mass and strength, 50
  - soft tissue, 51
  - visual impairment, 68
  - walking speed, 52-53
- fractures and, 50-51
  - vitamin D and, 51, 168-169, 170
- prevention of, 140-141
- vitamin D and, 51, 169

Family history, 59. See also *Genetic factors*.

Female athletic triad, 66

Femoral fractures. See also *Hip fractures*.

- atypical, bisphosphonates and, 206, 208-209, 245

Femoral neck

- bone composition of, 20, 22
- DXA of, 96-102

Femur, 22. See also *Femoral entries*.

Fibroblast growth factor-23 (FGF-23), 31

FIT (Fracture Intervention Trial), 190-191, 190

FLEX study, 190-191, 190

Forearm, bone densitometry of, 90, 96-97, 103

Forteo. See *Parathyroid hormone*.

Fosamax. See *Alendronate*.

Fracture(s). See also *specific types of fractures*.

- cause of, 81
- distal radius, 11
- fragility fractures, 84-86, 85
- FRAX (fracture risk assessment tool), 14, 68-71, 69, 70t-71t, 102

Fracture(s) (*continued*)

- hip, 11, 84
- mortality from, 11
- osteoporotic
  - annual direct costs from, 13
  - common sites of, 20
  - previous history of, 59, 70t, 84, 85
  - reduction with calcium intake, 158-160, 159
  - risk of. See *Fracture risk*.
  - sites of, 11, 20
  - vertebral, 11, 84, 85
- Fracture risk, 11. See also *DXA*.
  - age as predictor of, 49
  - assessment
    - initial, 276, 277
    - reassessment, 276, 278-279
  - assessment tools, 109-115
    - DXA, 89-90
    - Fracture Risk Calculator, 73, 109
    - FRAX, 14, 68-71, 69, 70t-71t, 102, 109
    - Garvan fracture risk calculator, 73, 110
    - QCT, 112-114, 113
    - Qfracture, 110
    - QUS, 110-112, 111
    - trabecular bone score, 115, 122
    - vertebral fracture assessment (VFA), 95, 114-115, 116-117, 118t, 120-121
    - websites for, 109-110
  - bone mass and, 43, 89-90
  - bone turnover and, 127
  - bone turnover markers and, 127, 132
  - calcium intake and, 158-160, 159
  - exercise and, 49, 138
  - falls and, 50-51
  - five main factors in, 44-51, 46
    - accelerated bone loss, 47-48
    - failure to achieve peak bone mass, 44-47
    - inadequate bone formation, 48-49
    - increased fall risk, 50-51
    - poor bone quality, 49-50
  - genetics and, 46, 60t
  - hormonal factors, 36, 60t-61t

Fracture risk (*continued*)  
 hyperthyroidism and, 36  
 leg length disparity and, 73  
 medications and, 62t, 67, 273-287  
   androgen deprivation therapy, 285-286  
   anti-epileptic drugs, 286  
   aromatase inhibitors, 281-285  
   cancer chemotherapy, 281, 284  
   glucocorticoids, 274-280  
   heparin, 286  
   proton pump inhibitors, 273  
   selective serotonin inhibitors (SSRIs), 274  
   SGLT2 inhibitors, 286-287  
   thiazolidinediones, 280  
   transplant anti-rejection medications, 280-281  
 osteoporosis and, 81  
 previous fractures and, 59, 70t, 84, 85  
 reduction by pharmacologic agents, 180t-181t  
 sedentary lifestyle and, 46-47, 49  
 in special populations, 267-292  
 vitamin D and, 168-169, 170  
 Fragility fractures, 84-86, 85  
   pharmacologic treatment and prevention, 183  
 Fragility of bone, 11  
 Framingham Study, 161  
 FRAX (fracture risk assessment tool), 14, 68-71, 69,  
   70t-71t, 102, 109  
   in DXA interpretation, 96, 102  
   threshold/indication for pharmacologic therapy, 183  
 FREEDOM trial, 215-220, 217, 218t  
 Frizzled, 30, 31, 262, 263

Gabapentin, 67  
 Garvan fracture risk calculator, 73, 110  
 Gastrointestinal diseases, 61t, 67  
 Gastrointestinal side effects, 204-205  
 Genetic factors  
   in osteoporosis/fracture risk, 60t, 63  
   peak bone mass and, 46, 63, 268  
 GIOP (glucocorticoid-induced osteoporosis).  
   See *Glucocorticoids, osteoporosis induced by*.  
 GLA-protein. See *Osteocalcin*.

Glucocorticoids, 32, 48, 49, 268-269, 274-280  
 bone formation/bone loss and, 36, 48, 49, 268-269,  
   274-280, 275  
 duration of treatment, 276  
 excess, 36  
 inhaled, 268-269, 274  
 intra-articular, 274  
 osteoporosis/fracture risk and, 48, 62t, 70t, 86, 274-280,  
   275  
   fracture risk assessments, 276, 277, 278-279  
 osteoporosis induced by (GIOP), 274-280  
   in children, 269  
   pathophysiology of, 275  
   pharmacologic treatment recommendations, 280, 282-283  
   prevention and treatment, 191, 192, 194, 276, 277  
   PTH and, 243-244  
   recommendations for patients receiving, 276-280  
 Gluten-free diet, 67  
 GnRH, 62t  
 Growth factors, 48  
 Growth hormone, 48  
 GSK-37, 262  
 Gynecologic factors in osteoporosis, 63-65

Haversian system, 21, 21  
 Heel. See *Calcaneus*.  
 Height, 72  
 Hematologic disorders, 61t  
 Heparin, 286  
 HERS study, 231  
 Hip  
   DXA of, 90, 94-95  
   analysis, 96-102  
   fractures of. See *Hip fractures*.  
   walking programs and, 140  
 Hip fractures, 11, 20, 84, 138, 141  
   bisphosphonates and (femoral fractures), 206, 208-209  
   family history of, 59  
   impact of, 11, 84t  
   mortality associated with, 11  
   reduced with mechanical hip protectors, 141, 142-143  
 Hip Intervention Program (HIP) trial, 194

- Hip protectors, mechanical, 141, *142-143*
- History, family, 59
- History, patient, 59, 60t-62t
- HORIZON trials, 199-202, *200*, 201t
- Hormonal factors
  - in bone formation/remodeling, 35-36
  - in osteoporosis/fracture risk, 60t-61t
- Hormone therapy (HT), 179, 231-233
  - for menopause, 63, 231-233
    - indicated for early menopause, 233
  - postmenopausal hormone replacement therapy, 179, 231-233
    - not approved for treatment of osteoporosis, 182
    - side effects, 231-233
    - risks of, 231-233
      - risk/benefit analysis, 232, *232*
- Hydroxyapatite, 22-23, 149
  - dissolution of, 26
- Hyperparathyroidism, 268, 271-273, *272*
  - osteoporosis risk and, 61t
  - secondary, 47
- Hyperprolactinemia, 60t, 66
- Hyperthyroidism, 36, 66
- Hypocalcaemia, 210
- Hypogonadal states, 60t, 86
- Hysterectomy, 65
- Ibandronate, 180t, 195-199. See also *Bisphosphonates*.
  - approved indications, 180t, 195-196
  - BONE study, 196
  - chemical structure, *184*
  - dosage and administration, 180t, 199
    - intravenous treatment, 198
    - oral treatment, 196-198
    - oral vs intravenous, 198-199
  - efficacy, 180t, 196-199
    - bone mineral density, 196-198, *197*
    - fracture risk reduction, 180t, 196
  - MOBILE study, 196-198, *197*
  - potency of, 195
  - side effects, 180t, 204
- Idiopathic osteoporosis, 43
- Immunosuppressive therapy, 280-281
- Inflammatory bowel disease, 269
- Inflammatory cytokines, 48
- Insulin-like growth factors (IGFs), 48
- Integrins
  - bisphosphonates and, 185
  - osteoclast function and, 259, *260*
- Interleukin-1 (IL-1), 26, 28, 48
- International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), 131
- Intracortical bone, 21, *21*
- Intramembranous bone, 19
- ISCD, criteria/recommendations for BMD testing, 90, 107-108
- Kidney disease, chronic, 271-273
- Kidney stones, 162
- Kyphoplasty, 143-146, *145*
- Kyphosis, 139
- Lactation, 64
  - osteoporosis risk and, 64-65
- LDL receptor-related proteins (LRP5/6), 262, *263*
- Leg length disparities, 73, *76-77*
- Levetiracetam, 67
- Lifestyle, 46-47, 63
  - modifications, 280
  - osteoporosis/fracture risk and, 46-47, 49, 60t, 63
  - risk factors, 63
  - sedentary, 46-47, 49
- Lipid levels, raloxifene and, 211
- Low bone mass (osteopenia), 25
  - WHO definition of, 82t
  - in women ages 50 and older, *13*
- Lumbar spine. See also *Vertebrae*.
  - bone mass in, *20*
    - T-scores and Z-scores for, 93
  - DXA of, 90, 91-96, *92-93*
- M-CSF (macrophage colony-stimulating factor), 26, 27, 34, 260
- Macrophage colony-stimulating factor. See *M-CSF*.

- Malabsorption, 61t, 67
- Markers. See *Bone turnover markers*.
- Marrow. See *Bone marrow*.
- Matrix metalloproteinases, 26
- Mechanical strength of bone. See *Bone strength*.
- Mechanical stress and force, 36-37
- Medicare/Medicaid services and follow-up testing, 108-109, 109t
- Medications
- bone loss and, 268-270, 273-287
  - decline in bone associated with, 13-14, 59
  - fall risk and, 51
  - osteoporosis/fracture risk and, 62t, 67, 273-287
    - androgen deprivation therapy, 285-286
    - anti-epileptic drugs, 286
    - aromatase inhibitors, 281-285
    - cancer chemotherapy, 281, 284
    - glucocorticoids, 268-269, 274-280
    - heparin, 286
    - proton pump inhibitors, 273
    - selective serotonin inhibitors (SSRIs), 274
    - SGLT2 inhibitors, 286-287
    - thiazolidinediones, 280
    - transplant anti-rejection mediations, 280-281
- Medroxyprogesterone (depo-medroxyprogesterone), 62t
- Men, 267-268
- causes of low BMD in, 86, 267-268
  - DXA screening in, 108, 109
  - osteoporosis in, 267-268
    - approved pharmacologic agents for, 268
- Menarche, late onset, bone mass and, 64
- Menopause, 63, 65
- bone loss after, 43, 44, 65
  - early/surgical, 60t, 63, 233
  - estrogen deficiency, 43, 47
  - hormone replacement therapy and, 63, 231-233
  - osteoporosis and, 43, 65
- Menstruation
- amenorrhea, exercise-induced, 60t, 66
  - history of, 64
  - late menarche, 64
- Metabolic disorders, 61t
- Microcrack repair, 33
- Microfractures, 49
- MK-5442, 263, 265
- MOBILE (Monthly Oral Ibandronate in Ladies) study, 196-198, 197
- MORE (Multiple Outcomes of Raloxifene Evaluation), 211
- Muscle mass, age-related loss of, 50
- Muscle strength, vitamin D and, 169, 172-173
- Musculoskeletal examination, 73, 74t, 76-77
- N-carboxytelopeptide (NTx), 128t, 130
- National Osteoporosis Foundation (NOF)
- on costs of osteoporotic fractures, 13
  - osteoporosis screening recommendation, 107-108
- NF-κB ligand, 26, 27, 260, 260
- NHANES (National Health and Nutrition Examination Survey), 83, 89, 156-157
- Nitric oxide, 37
- NOF. See *National Osteoporosis Foundation*.
- Non-collagenous proteins, 22-23
- Nonpharmacologic therapy, 137-148
- exercise and physical therapy, 137-140
  - fall prevention, 140-141
  - hip protectors, 141, 142-143
  - surgical intervention, challenges of, 146
  - vertebral stabilization, 142-146, 144, 145
- NTX (N-terminal cross-linking telopeptide), 128t, 130
- Nurse's Health Study, 161
- Nutrition, 63. See also *Diet*.
- Odanacatib, 260, 261
- Older persons. See *Elderly persons*.
- OPG. See *Osteoprotegerin*.
- Oral contraceptives, 269
- Oral hygiene, 205-206
- Orthostatic hypotension, 68, 72-73
- Osteoblasts, 26-31, 262-265
- bone formation biomarkers of, 28, 127
  - bone remodeling and, 26-31, 33, 34-35, 259
  - differentiation of, 26-31, 29, 262, 263
  - estrogen effects on, 47
  - glucocorticoids and, 49, 274, 275

### Osteoblasts (*continued*)

- mechanical force and, 37
  - novel therapeutic targets, 259, 262-265, 263
  - parathyroid hormone (PTH) and, 28, 234, 262, 263
  - physiology and therapeutic targets, 259, 262-265, 263
  - stimulators and inhibitors of, 32
  - vitamin D and, 163
  - Wnt/ $\beta$ -catenin signaling pathway and, 28, 30, 34, 37, 262-264, 263
- Osteocalcin (bone GLA-protein, BGP), 23, 34, 128t, 129
- Osteoclasts, 24-26, 259-261
- acidic environment created by, 26, 259
  - in bone loss, 44
  - bone remodeling and, 24-26, 27, 33, 34, 127, 259
  - calcitonin and, 227
  - cathepsin K and, 259, 261
  - differentiation of, 26, 27, 259-260
  - estrogen effects on, 37, 47
  - functions of, 24-26
  - mechanical force and, 37
  - novel therapeutic targets, 259-261, 260
  - parathyroid hormone and, 26, 234
  - physiology and therapeutic targets, 259-261, 260
  - ruffled border, 26, 28, 34
  - stimulators and inhibitors of, 26, 28
  - tyrosine src-kinase and, 261
- Osteocytes, 31, 33
- apoptosis, bisphosphonates and, 185
  - mechanical loading and, 31
- Osteoid, 33, 34-35
- Osteomalacia, 271
- Osteonecrosis of the jaw (ONJ), 205-206, 205, 245
- Osteopenia, 25
- prevalence in women ages 50 and older, 13
- Osteopontin, 23, 34
- Osteoporosis
- characteristics of, 25
  - in children, 268-270
  - definition of, 81-83, 82t
  - diagnosis of, 59-135
  - impact of, 11-17, 137
  - pathogenesis of, 43-57

### Osteoporosis (*continued*)

- prevalence in women ages 50 and older, 13-14, 13
  - prevention and treatment, 137-257
  - primary vs secondary, 43, 86-88
  - risk. *See Risk factors for osteoporosis.*
  - societal burden of, 11-17
  - in special populations, 267-292
- Osteoprotegerin (OPG), 26, 34, 47
- RANKL:OPG ratio, 26
- Osteosarcoma
- abaloparatide and, 270
  - parathyroid hormone and, 237
  - teriparatide and, 237, 270
- Paget's disease, 50, 238
- bisphosphonates for, 203
- Pain
- back pain, 59, 73
  - relief with vertebroplasty, 143
  - of spinal fractures, 137
- Pamidronate, 183, 203
- Parafollicular cells, 36
- Parathyroid hormone (PTH), 35, 181t, 233-244. *See also Abaloparatide; Hyperparathyroidism; Teriparatide.*
- action mechanisms, 35, 234
  - agents, 181t, 234
    - abaloparatide (PTHrP[1-34]), 181t, 234, 237-239
    - as recombinant human PTH, 234, 235
    - teriparatide (rhPTH[1-34]), 181t, 234, 235-237
  - analogues, 181t, 233-244
  - approved indications, 181t
  - biologic basis for anabolic effect, 233-234
  - black box warning for teriparatide, 235, 237
  - bone turnover and, 272
  - calcium level, maintenance of, 262, 265
  - calcium-sensing receptor (CaSR) and, 262, 263, 264-265
  - in CKD, 272
  - in combination with antiresorptive therapy, 239-243, 242, 243
  - cost of, 182, 246
  - dosage, formulations, and use, 181t
  - duration of therapy, 246

- Parathyroid hormone (PTH) (*continued*)  
 efficacy, 181t, 235, 238, 246  
 bone mineral density, 235, 236t  
 fracture risk reduction, 235, 236, 236t, 238, 240-241, 244, 245  
 glucocorticoid-induced osteoporosis and, 243-244  
 intact PTH (iPTH), 271-273  
 measurements of, 86  
 osteoblasts and osteoclasts, effects on, 26, 28, 32, 234, 262, 263  
 receptors, 35, 234, 237  
 side effects and safety concerns, 181t, 235-239  
 osteosarcoma, 237-238  
 trabecular connectivity and, 244, 245  
 vitamin D and, 35, 47
- Parenteral nutrition, 62t
- Parity, 64
- Pathogenesis of osteoporosis, 43-57  
 cortical bone loss, 44, 45  
 main factors in, 44-51, 46  
 trabecular bone loss, 43-44, 45
- Patient education, 15
- Peak bone mass, 23, 24, 44-47, 63
- Periosteum, 21, 21
- Peripheral sites, testing of, 106-107
- Pharmacologic treatment, 179-266. See also *specific agents*.  
 antiresorptive agents, 179, 180t-181t, 183-233  
 combinations not recommended, 182-183  
 bisphosphonates, 180t, 183-210  
 bone formation stimulants, 179, 181t, 245  
 calcitonin, 181t, 227-229  
 drug classes, 179, 180t-181t  
 efficacy of, 14, 180t-181t  
 concurrent calcium and vitamin D necessary, 15  
 fracture risk reduction, 180t-181t, 182  
 evolving pathways and therapeutic targets, 259-266, 260, 263  
 calcium-sensing receptor (CaSR), 262, 263, 264-265  
 cathepsin K, 259, 260, 261  
 DKK1, 262, 263, 264  
 sclerostin, 262-264, 263  
 tyrosine src-kinase, 260, 261
- Pharmacologic treatment (*continued*)  
 general guidelines for, 182-183  
 for glucocorticoid-induced osteoporosis (GIOP), 280, 282-283  
 hormone replacement therapy, 182-183, 231-233  
 indications for, 180t-181t, 183  
 long-term treatment, current perspective, 244-246  
 novel agents, 259-266, 260, 263  
 parathyroid hormone/PTH analogues, 181t, 233-244  
 RANKL inhibitor (denosumab), 181t, 214-227  
 risk/benefit ratio of, 15  
 safety of, 14-15, 244-245  
 selective estrogen receptor modulators, 181t, 210-214  
 strontium ranelate, 181t, 229-231
- Physical activity. See *Exercise*.
- Physical examination, 72-73, 74t
- Physical therapy, 139-140
- Physiology of bone, 19-42
- PICP (procollagen type I C-terminal peptide), 128t, 129, 130
- PINP (procollagen type I N-terminal peptide), 128t, 129, 130, 219
- Pioglitazone, 62t
- Prednisone, 48, 243
- Pregnancy  
 medications contraindicated in, 203  
 osteoporosis risk and, 64-65
- Prevention and treatment, 137-266. See also *specific therapies and agents*.  
 bone turnover markers in monitoring treatment, 132-133  
 calcium, 149-162  
 evolving pathways and therapeutic targets, 259-266  
 exercise and physical therapy, 137-140  
 hip protectors, 141, 142-143  
 long-term treatment, current perspective, 244-246  
 nonpharmacologic therapy, 137-148  
 pharmacologic agents, 179-266  
 evolving agents and therapeutic targets, 259-266, 260, 263  
 vertebral stabilization, 142-146, 144, 145  
 vitamin D, 162-169
- Primary osteoporosis, 43

Procollagen I terminal peptides, 128t, 129, 130  
Prostaglandins, 32, 37  
Prostate cancer, 228, 268, 285  
Proton pump inhibitors, 62t, 273  
PTH. See *Parathyroid hormone*.  
Pyridinium cross-links, 128t, 129-131, 130  
Pyridinoline, 128t, 130, 131

QCT (quantitative computed tomography), 112-114, 113  
Quality of life, impact of osteoporosis on, 11-17, 137  
Quantitative bone ultrasound (QUS), 106-107, 110-112, 111  
Quantitative computed tomography (QCT), 112-114, 113  
QUS. See *Quantitative bone ultrasound*.

Race. See *Ethnicity*.

Radius, 22

distal, fractures in, 11

Raloxifene, 181t, 210-212

action mechanism, 210

approved indications, 181t, 210, 280

as second-line treatment, 182

dosage, 181t, 212

efficacy, 211-212

side effects, 181t, 212

systemic beneficial effects, 210-211

RANK-RANKL, 26, 27, 34, 48, 260

bisphosphonates and, 185

in bone remodeling, 34, 35, 260, 260

estrogen and, 47

monoclonal antibody to. See *Denosumab*.

parathyroid hormone and, 35

RANKL:OPG ratio, 26

RANKL inhibitor. See *Denosumab*.

Reclast. See *Zoledronic acid*.

Remodeling of bone. See *Bone remodeling*.

Renal bone disease, 271-273

Renal impairment, bisphosphonates and, 207, 273

Renal stones, calcium intake and, 162

Resorption. See *Bone resorption*.

Rheumatic and autoimmune diseases, 61t

Rheumatoid arthritis (RA), 70t

Risedronate, 180t, 193-195. See also *Bisphosphonates*.

absorption of, 195

action mechanism, 193

approved indications, 180t, 193, 195

for men, 268

prevention and treatment of GIOP, 276

bone mineral density, 187-190, 188-189

chemical structure, 184

dosage, 180t, 193-194

daily dosing, 193-194

once-weekly and twice-monthly dosing, 194

efficacy, 180t, 193-194

fracture risk reduction, 180t, 192, 193-194

glucocorticoid-induced osteoporosis, 191, 192, 194, 276

formulation with calcium carbonate, 195

side effects, 180t

Risk factors for fractures. See *Fracture risk*.

Risk factors for osteoporosis, 59, 60t-62t, 63-68

central nervous system disorders, 61t

eating disorders, 60t, 65-66

endocrine disorders, 61t, 66

ethnicity/race, 11, 59

family history, 59

gastrointestinal diseases, 61t, 67

genetic factors, 60t, 63

gynecologic risk factors, 63-65

hematologic disorders, 61t

hypogonadal states, 60t, 86

lifestyle, 60t, 63

medications, 62t, 67

modifiable factors, 63

non-modifiable factors, 63

rheumatic and autoimmune diseases, 61t

Romosozumab, 263, 264

Rosiglitazone, 62t

RUNX2, 28, 29, 34

Salmon calcitonin. See *Calcitonin*.

Salt, high intake of, 60t

Saracatinib, 260, 261

Sarcopenia, 72

Scapular stabilization, 140

Sclerostin, 31, 262-264, 263  
 antibody against (romosozumab), 263, 264

Scoliosis, 73

Screening for osteoporosis, 106-110. See also *DXA*.  
 age at, 107-108, 107t  
 indications for DXA, 107t, 109t  
 recommendations for, 107-108, 107t, 109t  
 screening tests, 106-107

Secondary osteoporosis, 43, 86-88, 267. See also *Special populations*.  
 causes of, 86-88, 267  
 evaluating, 87t

Sedentary lifestyle, 46-47, 49, 60t

Selective estrogen receptor modulators (SERMs), 181t, 210-214, 281. See also *Raloxifene*; *Tibolone*.  
 toremifene, 285-286

Selective serotonin reuptake inhibitors (SSRIs), 62t, 274

SERMs. See *Selective estrogen receptor modulators*.

Sex hormones. See *Androgens*; *Estrogen*.

SGLT2 inhibitors, 286-287

Sialoprotein, 23

Skeleton, 19, 20. See also *Bone entries*.  
 axial vs appendicular, 19, 20  
 development in children, 269  
 functions of, 19  
 percentage of calcium in, 149

Smoking, 60t, 63, 70t, 280

Societal burden of osteoporosis, 11-17

Sodium glucose co-transporter-2 (SGLT2) inhibitors, 286-287

SOTI trial, 229, 230

Special populations, osteoporosis in, 267-292  
 children, 268-270  
 chronic kidney disease (CKD), 271-273  
 diabetics, 270  
 drugs that increase fracture risk, 273-287. See also *Medications*.  
 men, 267-268  
 renal bone disease, 271-273

Spinal fracture. See *Vertebral fractures*.

Spine. See also *Vertebrae*; *Vertebral entries*.  
 BMD (DXA) measurement of, 90, 91-96, 92-93

Spine (*continued*)  
 compression fractures, 146  
 exercise program and, 139

Src-kinase, 261  
 inhibitor (saracatinib), 260, 261

SSRIs (selective serotonin reuptake inhibitors), 62t, 274

STAR study (tamoxifen and raloxifene), 211

Steroids. See *Androgens*; *Estrogen*; *Glucocorticoids*.

Strength of bone. See *Bone strength*.

Strontium ranelate, 181t, 229-231  
 action mechanisms, 229  
 dosage and administration, 181t, 231  
 efficacy, 181t, 229-230, 245  
 indications for, 181t, 229  
 as second-line treatment, 182  
 long-term therapy, 245-246  
 not approved by FDA (U.S.), 182, 229  
 side effects and safety issues, 181t, 230-231, 245-246  
 SOTI trial, 229, 230  
 TROPOS trial, 229-230

Study of Osteoporotic fractures (SOF), 108

Surgical interventions  
 challenges of for, 146  
 indications for, 146  
 vertebral stabilization, 142-146, 144, 145

Syncope, 68

Systemic lupus erythematosus, 269

T-scores, 81-83, 82t, 88-89  
 hip, 95  
 lumbar spine, 93  
 normal, 82t, 83  
 not for use with premenopausal women, 83  
 reference values, 83, 89  
 wrist, 97

Tai Chi, 140

Tamoxifen, 62t, 281  
 STAR study (tamoxifen and raloxifene), 211

Tartrate-resistant acid phosphatase (TRACP5b), 128t, 130, 131

TBS score, 115, 122

Teriparatide (rhPTH[1-34]), 181t, 234, 235-237. See also *Parathyroid hormone (PTH)*.  
approved indications, 234, 235  
for glucocorticoid-induced osteoporosis, 276, 280  
for men, 268  
as second-line treatment, 182  
black box warning, 235, 237  
contraindications and warnings, 237, 269-270  
cost of, 182, 246  
dosage, 181t, 237  
efficacy, 235  
bone mineral density, 235, 236t  
fracture risk reduction, 235, 236, 236t  
as recombinant human PTH, 234, 235  
side effects, 235-237

Testosterone. See also *Androgens*.  
Testosterone deficiency, 44, 48  
Thiazolidinediones, 62t, 270, 280  
Thyroid hormones, 36. See also *Parathyroid hormone*.  
bone remodeling and, 36  
hyperthyroidism, 36, 66  
osteoporosis/fracture risk and, 62t  
Thyroid stimulating hormone (TSH), 86, 87t  
Tibolone, 179, 212-214. See also *Raloxifene*.  
action mechanism, 212  
dosage, 214  
efficacy, 213  
not FDA approved in U.S., 213  
side effects, 214  
Tiludronate, 203  
Topiramate, 67  
Toremifene, 285-286  
Trabecular bone  
anatomy of, 22  
changes with age, 25  
connectivity, PTH and, 244, 245, 246  
loss of, 43-44, 45  
percentage in different bones, 20, 22  
trabecular bone score, 115, 122  
Transplant anti-rejection mediations, 280-281  
Treatment of osteoporosis. See *Prevention and treatment*.

Trochanter, 20  
bone composition of, 20, 22  
TROPOS trial, 229-230  
Tumor necrosis factor (TNF), 26, 28, 48  
Turner's syndrome, 60t, 66  
Tyrosine src-kinase, 261  
inhibitor (saracatinib), 260, 261

Ultrasound, quantitative bone (QUS), 106-107, 110-112, 111  
US Preventive Services Task Force (USPSTF)  
recommendation on calcium, 160  
screening recommendation, 107-108  
UV-B irradiation, vitamin D and, 163, 164

Vertebrae. See also *Lumbar spine; Spine; Vertebral entries*.  
bone composition of, 20, 22  
deformation patterns, 114-115, 120-121  
vertebral stabilization, 142-146, 144, 145  
Vertebral deformation patterns, 114-115, 120-121  
Vertebral Fracture risk, prevalent fractures and, 11  
Vertebral fractures, 20, 84, 146  
asymptomatic, 11  
compression fractures, 146  
disability from, 11  
impact of, 137  
mortality associated with, 11  
pain from, 137  
pain relief techniques  
kyphoplasty, 143-146, 145  
vertebroplasty, 142-143, 144  
previous fractures and future fracture risk, 84, 85  
recurrence of, 11  
vertebral deformation patterns, 114-115, 120-121  
vertebral fracture assessment (VFA), 95, 114-115, 116-117, 120-121  
indications for, 114, 118t  
Vertebral stabilization, 142-146  
complications of, 143-146  
kyphoplasty, 143-146, 145  
pain relief, 143  
vertebroplasty, 142-146, 144

- Vertebroplasty, 142-143, 144  
 complications of, 143-146
- Vertigo, 51, 68
- Visual impairment, falls and fractures and, 68
- Vitamin A (retinol), excess, 60t
- Vitamin D, 162-169. See also *Calcium*.  
 action mechanisms, 162, 164-165  
 active form ( $1\alpha,25(\text{OH})_2\text{D}_3$ ), 26, 28, 35, 162  
 anticonvulsants and, 67  
 assessment, 168  
 biological pathways, 162, 164-165  
 bone metabolism and, 163  
 calcium absorption and, 156  
 deficiency, 46-47  
 fall risk and, 51  
 as risk factor for osteoporosis, 46-47, 60t, 63  
 dietary intake recommendations, 150t-151t  
 Dietary Reference Intakes for, 150t-151t  
 dietary sources, 163, 166t-167t  
 fall/fracture risk and, 51, 168-169, 170  
 food label, 157, 163  
 fracture reduction and, 168-169, 170  
 intake  
 in children, 269  
 dietary sources, 163, 166t-167t  
 fracture reduction with, 158-160, 159  
 necessary for efficacy of anti-osteoporosis medications, 15  
 optimal daily, 168  
 recommended daily, 150t-151t, 163  
 in special populations, 269, 270, 280, 285, 286  
 malabsorption of, 67  
 measurement of, 86  
 muscle, effects on, 169, 172-173  
 parathyroid hormone and, 47  
 sources and function, 163, 164-165  
 supplementation, 63, 168  
 excessive, 271  
 toxicity, 169
- Walking, 138, 140  
 back pain and, 140  
 speed, fall direction and, 52-53
- Weight, 72  
 low/loss, as risk factor, 62t
- WHI. See *Women's Health Initiative (WHI)*.
- White women. See *Caucasian women*.
- Wnt ligands, 28-31, 30  
 Wnt/ $\beta$ -catenin signaling pathway, 28, 30, 34, 37, 262, 263  
 inhibitors of, 262-264, 263  
 DKK1 (dickkopf-1), 31, 262, 263  
 sclerostin, 262-264, 263
- Women's Health Initiative (WHI), 182, 231
- Women's Health Trial, 161
- World Health Organization (WHO), definition of  
 osteoporosis, 81-83, 82t
- Wrist fractures, 20, 86
- Z-scores, 83, 88-89  
 ethnicity database for, 83, 89  
 hip, 95  
 lumbar spine, 93  
 reference values, 83, 89  
 wrist, 97
- Zoledronic acid, 180t, 199-203, 285. See also  
*Bisphosphonates*.  
 for androgen deprivation therapy, 285  
 approved indications, 180t, 199, 202  
 for glucocorticoid-induced osteoporosis, 276  
 for men, 268  
 cautions and contraindications, 203  
 chemical structure, 184  
 dosage and administration, 180t, 202-203  
 intravenous, 199, 202-203  
 drug "holiday," 245  
 efficacy, 180t, 199-203  
 bone mineral density, 202, 285  
 fracture risk reduction, 180t, 199-202, 200, 201t  
 HORIZON trials, 199-202, 200, 201t  
 side effects, 180t, 207, 209